A Phase II, Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Selective Progesterone Receptor Modulator Proellex (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
To evaluate Proellex administered once daily in pre-menopausal women with symptomatic leiomyomata
91 days
Yes
Andre VanAs, PhD, MD
Study Director
Repros Therapeutics Inc.
United States: Food and Drug Administration
ZPU-003
NCT00882258
March 2006
March 2007
Name | Location |
---|---|
Visions Clinical Research | Boynton Beach, Florida 33472 |
Women's Health Research | Phoenix, Arizona 85015 |
Alabama Clinical Therapeutics, Llc | Birmingham, Alabama 35235 |
Downtown Women's Health Care | Denver, Colorado 80218 |
Insignia Clinical Research (Tampa Bay Women's Center) | Tampa, Florida 33607 |
SC Clinical Research Center | Columbia, South Carolina 29201 |
Advances in Health Inc. | Houston, Texas 77030 |
Arizona Wellness Centre for Women | Phoenix, Arizona 85032 |
Visions Clinical Research Tuscon | Tuscon, Arizona 85712 |
Women's Health Care, Inc. | San Diego, California 92123 |
Medical Centre for Clinical Research | San Diego, California 92108 |
Miami Research Associates, Women's Health Studies | Miami, Florida 33143 |
Caring for Women | Las Vegas, Nevada 89106 |
Affiliated Clinical Research, Inc. | Las Vegas, Nevada 89128 |
Obstetrical & Gynecolgical Associates, PA (OGA) | Houston, Texas 77054 |
Women's Clinical Research Centre | Seattle, Washington 98105 |